Changes in Renal Function Tests During Short‐Term Administration of Oral Fosravuconazole for Tinea Pedis

Y.T. has received consulting fees and speaker's fees from Sato Pharmaceutical Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Kaken Pharmaceutical Co. Ltd., and Maruho Co. Ltd. Y.T. is also an Editorial Board member of The Journal of Dermatology and the lead author of this article. To minimize bias, Y.T. was excluded from all editorial decision-making related to the acceptance of this article for publication. S.K. has received consulting fees and speaker's fees from Sato Pharmaceutical Co. Ltd. Y.N. and S.H. are employees of Sato Pharmaceutical. Co. Ltd. W.N. has received consulting fees and speaker's fees from Sato Pharmaceutical Co. Ltd. and Eisai Co. Ltd. Data sharing not applicable to this article as no datasets were generated or analysed during the current study. Table S1: Criteria for renal dysfunction due to F-RVCZ. Table S2: List of cases that met the criteria for renal dysfunction, along with their Scr and eGFR values. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.